Free Trial
NASDAQ:NEUP

Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Neuphoria Therapeutics logo
$11.33 -0.88 (-7.21%)
As of 08/29/2025 04:00 PM Eastern

About Neuphoria Therapeutics Stock (NASDAQ:NEUP)

Key Stats

Today's Range
$10.50
$13.34
50-Day Range
$6.05
$12.21
52-Week Range
$2.12
$13.34
Volume
125,912 shs
Average Volume
53,452 shs
Market Capitalization
$21.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Neuphoria Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

NEUP MarketRank™: 

Neuphoria Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 713th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Neuphoria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Neuphoria Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Neuphoria Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.85) per share.

  • Price to Book Value per Share Ratio

    Neuphoria Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Neuphoria Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for NEUP.
  • Dividend Yield

    Neuphoria Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Neuphoria Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for NEUP.
  • News Sentiment

    Neuphoria Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Neuphoria Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    4 people have searched for NEUP on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Neuphoria Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.69% of the stock of Neuphoria Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 15.90% of the stock of Neuphoria Therapeutics is held by institutions.

  • Read more about Neuphoria Therapeutics' insider trading history.
Receive NEUP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuphoria Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NEUP Stock News Headlines

Equities Analysts Offer Predictions for NEUP Q4 Earnings
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.tc pixel
Neuphoria Therapeutics' (NEUP) Buy Rating Reaffirmed at HC Wainwright
NEUP Neuphoria Therapeutics Inc. - Seeking Alpha
Neuphoria Therapeutics Inc. (NEUP) - Yahoo Finance
See More Headlines

NEUP Stock Analysis - Frequently Asked Questions

Neuphoria Therapeutics' stock was trading at $3.20 at the beginning of 2025. Since then, NEUP stock has increased by 254.1% and is now trading at $11.33.

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) announced its earnings results on Tuesday, May, 20th. The company reported $6.55 earnings per share for the quarter, beating the consensus estimate of ($0.47) by $7.02. The company had revenue of $15 million for the quarter.

Top institutional shareholders of Neuphoria Therapeutics include AdvisorShares Investments LLC (3.60%).

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/20/2025
Today
8/29/2025
Next Earnings (Estimated)
9/29/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NEUP
Previous Symbol
NASDAQ:NEUP
CIK
1191070
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$21.00
Potential Upside/Downside
+85.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.01
Quick Ratio
11.01

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
2,130.04
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.85 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
1,880,000
Free Float
1,867,000
Market Cap
$21.30 million
Optionable
N/A
Beta
0.53
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NEUP) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners